MOYOM Biotech Raises New Round from Cathay Consumer Co-Creation Fund

PR Newswire··CNEU·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

MOYOM Biotech has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to accelerate its global growth in regenerative aesthetics. The fund was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government to foster innovation in beauty, health and skin science. Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite regenerative materials, and its flagship brand Aphranel® received Class III medical device registration from China's National Medical Products Administration in February 2025 and certification under the European Union Medical Device Regulation in May 2026. Since its commercial launch in May 2025, Aphranel® has been introduced in more than 700 medical aesthetics clinics across China. Leveraging Cathay Capital's global ecosystem, MOYOM plans to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets while continuing to invest in next-generation regenerative biomaterials.

Impact on assets 2

Consumer Staples▲ · 1 stocks
LOréal S.A.
OR
▲ PositiveCapitalrelevance

L'Oréal co-established the Cathay Consumer Co-Creation Fund that is investing in MOYOM Biotech, expanding its beauty/skin-science innovation ecosystem

Materials▲ · 1 stocks

Off-coverage companies 2

MOYOM BiotechPrivate▲ Positive
Capitalrelevance

MOYOM Biotech completed a new financing round from the Cathay Consumer Co-Creation Fund to accelerate global growth in regenerative aesthetics

Cathay CapitalPrivate▲ Positive
Capitalrelevance

Cathay Capital, via its Cathay Consumer Co-Creation Fund, made the investment in MOYOM Biotech

© 2026 MarketIVNews